(d) for each patented invention to which the application relates, the name of the patentee of the invention and the number, as recorded in the Patent Office, of the patent issued in respect of that invention;

In particular, the representatives of small and medium-sized enterprises (SMEs) highlighted the importance of moderate patenting costs.

In particular, the representatives of small and medium-sized enterprises (SMEs) highlighted the importance of moderate patenting costs.

This proposal is accompanied by an impact assessment which identifies the main problems in the current European patent system: (i) high costs related to translation and publication of European patents, (ii) differences in the maintenance of patents in the Member States (annual renewal fees have to be paid each year in each country where the patent is validated); and (iii) administrative complexity of registering transfers, licences and other rights related to patents.

As you point out, we've filed 39 patents, quite a number of licence negotiations are under way, and a number of licences have been granted.

It includes the name of the pharmaceutical product that is to be manufactured and sold for export under an authorization; the prescribed information in respect of the version of the product to be manufactured for export, which is there to pick up things such as the size, shape, and colour, as well as other distinguishing attributes; the maximum quantity of the product, which will be taken from the WTO website; the name of the patentee or patentees and the number of the patented invention as recorded in the Patent Office; the name of the importing jurisdiction; the name of the purchaser if it's not the importing jurisdiction itself; ...[+++] and any other information that may be prescribed, which is a safety valve in case something else is needed.